Last reviewed · How we verify

NCT07531108

Effects of Empagliflozin-Metformin, Sitagliptin-Metformin, and Metformin on Adipokines in Type 2 Diabetes

Completed Phase 4 Last updated 15 April 2026
What this trial tests

Phase 4 trial testing Empagliflozin-Metformin in Diabetes Mellitus, Type 2 in 186 participants. Completed in 27 November 2025.

Timeline
15 November 2024
Primary endpoint
27 November 2025
27 November 2025

Quick facts

Lead sponsorHawler Medical University
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment186
Start date15 November 2024
Primary completion27 November 2025
Estimated completion27 November 2025
Sites1 location across Iraq

Drugs / interventions tested

Conditions studied

Sponsor

Hawler Medical University

Who can join

Adults 35 to 75, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study compared the impacts of empagliflozin-metformin, sitagliptin-metformin, and metformin monotherapy in treatment-naive overweight or obese adults with newly diagnosed type 2 diabetes mellitus in Erbil, Iraq. The study monitored participants for 12 weeks. It determined changes in serum omentin-1, resistin, glycemic markers, and anthropometric measures.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

Other Hawler Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07531108.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing